Dabbling in CD47, Pfizer infuses $25M into a biotech player touting positive monotherapy data
Pfizer is following Gilead, AbbVie, Boehringer and a string of biotech upstarts into the CD47 race, lining up its own shots at the “don’t eat …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
